What is the role of imaging studies in the treatment of early-stage, low risk Hodgkin lymphoma (Hodgkin disease)?

Updated: Sep 12, 2018
  • Author: Bradley W Lash, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

As discussed under Goals of Therapy and Response Assessment, there is increasing use of mid-treatment positron-emission tomography (PET) scans to guide therapy. Current NCCN guidelines recommend the use of interim PET-CT scans to guide therapy when ABVD is chosen as the initial regimen, regardless of the initial stage of disease. [4]

However, although it is clear that such scans have prognostic value, it remains unclear whether altering therapy based on PET scan results improves treatment outcomes in early-stage disease. [69, 70] The current data support the monitoring of patients with history and physical examination prior to administering each cycle or modality of treatment and prior to obtaining laboratory studies and CT scans. Some experts suggest that PET scans should not be used to alter therapy outside of a clinical trial.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!